Financial Contrast: H. Lundbeck A/S (OTCMKTS:HLUYY) vs. EVN (OTCMKTS:EVNVY)

H. Lundbeck A/S (OTCMKTS:HLUYY) and EVN (OTCMKTS:EVNVY) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends and institutional ownership.

Analyst Recommendations

This is a breakdown of recent recommendations for H. Lundbeck A/S and EVN, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
H. Lundbeck A/S	1	1	0	0	1.50
EVN	0	0	0	0	N/A

Volatility and Risk

H. Lundbeck A/S has a beta of 0.68, meaning that its stock price is 32% less volatile than the S&P 500. Comparatively, EVN has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500.

Earnings and Valuation

This table compares H. Lundbeck A/S and EVN’s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
H. Lundbeck A/S	$2.59 billion	8.45	$209.69 million	$0.88	25.00
EVN	$2.36 billion	1.33	$223.78 million	N/A	N/A

EVN has lower revenue, but higher earnings than H. Lundbeck A/S.

Profitability

This table compares H. Lundbeck A/S and EVN’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
H. Lundbeck A/S	6.74%	13.74%	7.16%
EVN	N/A	N/A	N/A

Dividends

H. Lundbeck A/S pays an annual dividend of $0.20 per share and has a dividend yield of 0.9%. EVN pays an annual dividend of $0.08 per share and has a dividend yield of 2.3%. H. Lundbeck A/S pays out 22.7% of its earnings in the form of a dividend.

Summary

H. Lundbeck A/S beats EVN on 5 of the 9 factors compared between the two stocks.

About H. Lundbeck A/S

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership agreement with Verantos to focus on a study to enable real-world evidence in support of migraine therapy; and collaboration with Rgenta Therapeutics, Inc. The company was founded in 1915 and is headquartered in Valby, Denmark.

About EVN

EVN AG provides energy and environmental services for private and business customers, as well as municipalities in Austria, Bulgaria, Croatia, Germany, and Albania. The company operates through Energy, Generation, Networks, South East Europe, Environmental, and Other segments. It generates electricity from thermal sources and renewable energies; and procures, trades, and sells electricity and natural gas to end customers and on wholesale markets, as well as generates and sells heat. The company also operates regional electricity and natural gas networks, as well as cable TV and telecommunications networks. In addition, it is involved in drinking water supply, wastewater disposal and treatment, thermal waste utilisation, and international project business activities. The company was founded in 1922 and is headquartered in Maria Enzersdorf, Austria. EVN AG is a subsidiary of NÖ Landes-Beteiligungsholding GmbH.